Table 1.
Comparison of pathologic melanoma characteristics and proportion of melanoma stages according to the American Joint Committee on Cancer 8th edition staging system between ‘2020 post‐lockdown’ (=P2) and ‘2019 reference post‐lockdown’ (=P4) periods
|
2020 post‐lockdown (P2) N = 181 |
2019 reference post‐lockdown (P4) N = 192 |
P value | |
|---|---|---|---|
| AJCC 8th edition staging | |||
| In situ | 34 (19) | 36 (19) | 0.99 |
| Stage I | 87 (48) | 117 (61) | 0.01 |
| IA | 64 (35) | 93 (48) | 0.01 |
| IB | 23 (13) | 24 (13) | 0.95 |
| Stage II | 34 (19) | 25 (13) | 0.13 |
| IIA | 12 (7) | 13 (7) | 0.96 |
| IIB | 8 (4) | 8 (4) | 0.90 |
| IIC | 14 (8) | 4 (2) | 0.01 |
| Stage III | 24 (13) | 11 (6) | 0.01 |
| IIIA | 2 (1) | 3 (2) | 0.99 |
| IIIB | 8 (4) | 2 (1) | 0.06 |
| IIIC | 14 (8) | 6 (3) | 0.06 |
| IIID | 0 (0) | 0 (0) | 0.99 |
| Stage IV | 2 (1) | 3 (2) | 0.99 |
| Histological subtypes | |||
| SSM | 122 (67) | 133 (69) | 0.70 |
| Nodular | 23 (13) | 17 (9) | 0.23 |
| Acrolentiginous | 8 (4) | 6 (3) | 0.59 |
| LM/LMM | 24 (13) | 26 (14) | 0.94 |
| Mucosal | 0 (0) | 2 (1) | 0.50 |
| Unclassifiable | 2 (1) | 6 (3) | 0.29 |
| Unknown | 2 (1) | 2 (1) | 0.99 |
| Breslow index mean, mm (±SD) | 2.2 (±2.4) | 1.6 (±2.8) | <0.001 |
| Presence of ulceration | 41 (23) | 18 (9) | 0.001 |
| Presence of mitoses | 58 (32) | 49 (26) | 0.32 |
| Presence of regression | 10 (6) | 11 (6) | 0.73 |
| Presence of neurotropism | 8 (4) | 0 (0) | 0.007 |
| Presence of angiotropism | 4 (2) | 2 (1) | 0.68 |
P: Student or Wilcoxon tests for quantitative/continuous variables, Chi‐Square or Fisher tests for qualitative/categorical variables (R‐studio Version 1.2.5033). Numbers (percentage).
AJCC, American Joint Committee on Cancer; SSM, superficial spreading melanoma; LM, lentigo maligna; LMM, lentigo maligna melanoma; SD, standard deviation.